spacer
home > pmps > summer 2017 > of paramount importance
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Of Paramount Importance

Parenterals are an important segment within the drug delivery field, assuming approximately 30% of the market share. One factor driving this is the substantial emergence of new therapeutic antibodies and advancements in biotechnology, resulting in many improved medications that have led to enhancements in patient wellbeing and life expectancy (1,2).

The realisation and proliferation of recombinant DNA technology led to the development of protein drugs. In particular, the development of monoclonal antibodies (mAbs) as drugs has increased significantly over the past few years. From 2014 onwards, 64 mAbs have been approved, are pending or are in review in Europe and the US. Additionally, more than 200 are in a clinical study stage. As explained by Dr Steven J Shire, mAbs are very specific, binding to a single antigen target, which may lead to fewer side effects than small molecule drugs (3).

Product Control


Biopharmaceuticals are frequently administered through injection using pre-filled syringes (PFSs); however, proteins are inherently unstable, sensitive to heat and oxidisation and have the propensity to aggregate (4-6). This generates the need to control the stability and quality of the drug product (DP), mitigating possible interactions in a risk-based approach for preventing effects on drug efficacy, pharmacokinetics and clinical consequences affecting patient safety.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
William Dierick is Director of Technology Development – Global Pharmaceutical Solutions at Terumo: a global R&D company that offers drug delivery devices and injection technology, cardiology and cardiovascular systems, transfusion, patient monitoring and clinical systems. With 40 years of experience in the medical and pharma sector, he has held various positions in the company, covering quality assurance, production and product development to marketing, corporate planning and business development. William serves as expert of ISO/TC76 and ISO/TC84 and is an active member of MedTech Europe and volunteer at PDA.

Dr Piet Christiaens is Scientific Director at Toxikon Europe where he develops analytical methods and protocols for E&L studies for the medical and pharma industries. He oversees all laboratory operations at the company and is supporting the European business development. Piet received his PhD from the Analytical Chemistry Department of the University of Leuven, Belgium, in 1991. 

Dr Wim Van Rossom graduated with an MSc in organic chemistry in 2006 and received his PhD in 2010 from the Catholic University of Leuven, Belgium. In 2011, he moved to Japan where he spent two years as a Postdoctoral Fellow at the National Institute for Materials Science designing synthetic approaches towards macrocyclic structures. He was selected by the European Commission for a Marie Curie Career Integration Grant in 2013 to continue his research at the University of Southampton, UK, as Research Fellow on the topics of supramolecular anion recognition and transmembrane anion transport. Since 2015, he has been Study Director at Toxikon Europe, focusing on E&L studies in parenteral applications. 
spacer
William Dierick
spacer
spacer
spacer
Dr Piet Christiaens
spacer
spacer
spacer
Dr Wim Van Rossom
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

HATRIC-based identification of receptors for orphan ligands (small molecules)

HATRIC-LRC (Ligand Receptor Capture) enables now the identification of small molecule targets on the surface of living cells! Even primary cells!
More info >>

White Papers

Device Develop for Combo Products

Phillips-Medisize

Combination products are defined as therapeutics combining two or more products (drug/device, biologics/device, biologics/drugs or drug/device/biologics), regulated and sold as a single unit. As these pharmaceutical and biological therapies and treatments have evolved, so has the need to develop appropriate delivery mechanisms for these applications. When developing a combination product, there are many things that need to be considered – the critical relationships between device development and the pharmaceutical or biologic, early establishment of regulatory and clinical strategies, understanding ‘user’ needs, determining product requirements, as well as, device manufacturing variation.
More info >>

 
Industry Events

SMi presents the 2nd annual conference on Pharmaceutical Microbiology West Coast

6-8 June 2018, Crowne Plaza, San Diego, CA, USA

SMi proudly presents the 2nd Annual Pharmaceutical Microbiology West Coast Conference, in San Diego, USA, on the 7th and 8th of June 2018. Delivering updates and promoting discussion on key challenges and developments within the pharmaceutical microbiology industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement